Safety of Intravenous Edaravone in Clinical Practice

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Intravenous (IV) edaravone is approved for ALS treatment in the United States.
• Post-marketing surveillance is crucial for assessing long-term drug safety.

Purpose of the Study:

• To summarize the post-marketing pharmacovigilance safety data of IV edaravone.
• To evaluate safety during the first 1 and 3 years after IV edaravone launch for ALS.
• To identify any new safety signals associated with IV edaravone.

Main Methods:

• Analysis of post-marketing safety data from pharmacovigilance reports.
• Review of adverse events (AEs) and serious adverse events (SAEs) reported.
• Comparison of safety data with previous clinical trial findings.

Main Results:

• Most frequently reported AEs and SAEs were consistent with ALS disease progression (e.g., fatigue, muscular weakness).
• Administration site reactions and five non-fatal anaphylaxis SAEs were associated with IV administration.
• No new safety signals were identified; IV edaravone demonstrated a favorable safety profile.

Conclusions:

• IV edaravone maintains a favorable safety profile in real-world post-marketing use for ALS.
• Findings support the transition to oral edaravone suspension, mitigating IV-related complications.
• Ongoing safety assessments are vital for informing ALS treatment strategies.